AISTHESIS provides real-time insights into the sensory experiences of children with autism, helping caregivers understand the triggers behind distress behaviors. By identifying the specific sensory inputs causing overload, AISTHESIS enables targeted interventions and support for children on the autism spectrum.
Funding
Funding not disclosed
Founders
Product
Problem
Children with sensory processing disorder (SPD) often struggle to communicate their sensory needs, making it difficult for caregivers to provide timely and effective support. Parents and therapists lack personalized, real-time data to understand a child's unique sensory profile and tailor interventions accordingly. This can lead to challenges in reinforcing therapeutic strategies outside of formal sessions.
Solution
AISTHESIS offers an AI-powered platform designed to provide personalized, real-time recommendations for children with SPD. The system uses a smart wearable device to track biometric and environmental data, which is then processed by AI algorithms to identify specific sensory triggers. Caregivers receive real-time alerts and actionable recommendations through a mobile and web application, enabling them to proactively manage sensory sensitivities. Long-term insights derived from the data help improve therapy effectiveness and optimize daily routines for children with SPD. The platform aims to empower caregivers with data-driven insights, facilitating better support and improved outcomes.
Target Audience
The primary target audience includes parents, therapists, and educators of children with sensory processing disorder (SPD).
Features
- Smart wearable device for continuous biometric and environmental data collection
- AI-powered data processing to identify individual sensory triggers
- Real-time alerts and personalized recommendations delivered via mobile and web applications
- Cloud-based SaaS platform integrating edge and cloud processing
- Long-term data analysis to improve therapy and daily routines
- Secure data storage and HIPAA compliance (in progress, pending FDA approval)